ClinicalTrials.gg
CompletedNCT05180162Updated Mar 21, 2025

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

A Phase 1 interventional study of 68Ga-FAP-2286 and Positron Emission Tomography (PET) in Liver Fibrosis, Pulmonary Fibrosis and Myocardial Fibrosis, sponsored by Thomas Hope. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Thomas Hope · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 231 studies in Liver Cirrhosis with a site in United States — 45 open to participants now, 63 under way, 3 of them phase 3. Liver Cirrhosis · United States.

Enrollment
139th of 166
16 · median 55
Started
2021
with 18 others
Phase 1
26 of 231
4 open now
Registered
159th of 231
by date

Among the 231 studies in Liver Cirrhosis with a site in United States, this one is the 139th largest by enrollment of the 166 interventional ones that give a count, is one of 19 that started in 2021, is one of 26 in phase 1, and was the 159th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

45 of the 231 studies in Liver Cirrhosis with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Liver Cirrhosis with a site in United States, or all of them as a file.
02

Study summary

This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis.

FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.

Read the detailed description

PRIMARY OBJECTIVES:

I. All cohorts: Safety of 68Ga-FAP-2286.

II. Cohort 1: Measured uptake of radiotracer (SUVpeak) in regions of known liver fibrosis.

III. Cohort 2: Measured uptake of radiotracer (SUVpeak) in regions of known pulmonary fibrosis.

IV. Cohort 3: Measured uptake of radiotracer (SUVpeak) in regions of myocardial fibrosis.

EXPLORATORY OBJECTIVES:

I. Correlation of 68Ga-FAP-2286 uptake with FAP expression determined by immunohistochemistry.

II. Compare 68Ga-FAP-2286 scan results to archival Computerized tomography (CT), magnetic resonance imaging (MRI), or Positron Emission Tomography (PET) images.

Patients will receive a single administration of 68Ga-FAP-2286 prior to PET imaging and will be followed for up to two hours after the injection of 68Ga-FAP-2286 for evaluation of adverse events.

03

Conditions studied

  • Liver Fibrosis
  • Pulmonary Fibrosis
  • Myocardial Fibrosis

Keywords

  • Positron Emission Tomography (PET)
  • Imaging
  • 68Ga-FAP-2286
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 18 years.
  2. Confirmed pathologic fibrosis in one of the following cohorts

    1. Cohort 1: Hepatic fibrosis, based on cirrhosis on imaging or hepatic fibrosis on liver .
    2. Cohort 2: Pulmonary fibrosis, based on CT findings or biopsy of lung parenchyma.
    3. Cohort 3: High likelihood of cardiac fibrosis as indicated by known cardiac sarcoidosis or amyloidosis (shown on MRI or Fluorodeoxyglucose (FDG) PET), recent myocardial infarction within the last 30 days (as shown by an elevated troponin), known cardiotoxicity (decreased on systemic therapy), or other known inflammatory or infiltrative disease.
  3. Ability to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
  2. Known pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort 1: Liver Fibrosis

    Patients with liver fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.

    Drug: 68Ga-FAP-2286 · Procedure: Positron Emission Tomography (PET)

  • Experimental
    Cohort 2: Pulmonary Fibrosis

    Patients with pulmonary fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.

    Drug: 68Ga-FAP-2286 · Procedure: Positron Emission Tomography (PET)

  • Experimental
    Cohort 3: Myocardial Fibrosis

    Patients with myocardial fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.

    Drug: 68Ga-FAP-2286 · Procedure: Positron Emission Tomography (PET)

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with treatment-related adverse events

    Proportion of participants with Adverse Events, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported.

    Time frame: Up to 31 days

  2. Median peak standardized uptake value (SUVpeak) in liver region

    The median SUVpeak in regions of known liver fibrosis will be reported with 95% confidence intervals

    Time frame: Up to 1 days

  3. Median peak standardized uptake value (SUVpeak) in lung region

    The median SUVpeak in regions of known pulmonary fibrosis will be reported with 95% confidence intervals

    Time frame: Up to 1 days

  4. Median peak standardized uptake value (SUV) in myocardium region

    The median SUVpeak in regions of known myocardial fibrosis will be reported with 95% confidence intervals

    Time frame: Up to 1 days

07

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94122, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in May 2024, 29 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2021
First posted
Jan 6, 2022
StartActual
Dec 9, 2021
Primary completionActual
May 28, 2024
CompletionActual
May 28, 2024
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05180162
Lead sponsor
Thomas Hope
Collaborators
Clovis Oncology, Inc.
Responsible party
Thomas Hope (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Jan 6, 2022
Start date
Dec 9, 2021
Primary completion
May 28, 2024
Completion
May 28, 2024
Last update
Mar 21, 2025

Study contacts

Thomas A Hope, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium (68GA) rofapitide tetraxetan

Start the discussion